AIM: Human beta-defensin (HBD)-1 and HBD-2 are endogenous antimicrobial peptides. Unlike HBD-1, the HBD-2 expression is augmented by Helicobacter pylori (H pylori). We sought to determine HBD-1 and HBD-2 concentrations in gastric juice during H pylori infection. METHODS: HBD-1 and HBD-2 concentrations were measured by radioimmunoassay in plasma and gastric juice of 49 H pylori-infected and 33 uninfected subjects and before and after anti-H pylori treatment in 13 patients with H pylori-associated gastritis. Interleukin (IL)-1beta and IL-8 concentrations in gastric juice were measured by enzyme-linked immunosorbent assay (ELISA). Histological grades of gastritis were determined using two biopsy specimens taken from the antrum and corpus. Reverse phase high performance liquid chromatography (RP-HPLC) was used to identify HBD-2. RESULTS: HBD-2 concentrations in gastric juice, but not in plasma, were significantly higher in H pylori-positive than -negative subjects, albeit the post-treatment levels were unchanged. Immunoreactivity for HBD-2 was exclusively identified in H pylori-infected mucosa by RP-HPLC. HBD-2 concentrations in gastric juice correlated with histological degree of neutrophil and mononuclear cell infiltration in the corpus. IL-1beta levels correlated with those of IL-8, but not HBD-2. Plasma and gastric juice HBD-1 concentrations were similar in H pylori-infected and uninfected subjects. CONCLUSION: Our results place the beta-defensins, especially HBD-2, in the front line of innate immune defence. Moreover, HBD-2 may be involved in the pathogenesis of H pylori-associated gastritis, possibly through its function as immune and inflammatory mediator.
AIM: Humanbeta-defensin (HBD)-1 and HBD-2 are endogenous antimicrobial peptides. Unlike HBD-1, the HBD-2 expression is augmented by Helicobacter pylori (H pylori). We sought to determine HBD-1 and HBD-2 concentrations in gastric juice during H pylori infection. METHODS: HBD-1 and HBD-2 concentrations were measured by radioimmunoassay in plasma and gastric juice of 49 H pylori-infected and 33 uninfected subjects and before and after anti-H pylori treatment in 13 patients with H pylori-associated gastritis. Interleukin (IL)-1beta and IL-8 concentrations in gastric juice were measured by enzyme-linked immunosorbent assay (ELISA). Histological grades of gastritis were determined using two biopsy specimens taken from the antrum and corpus. Reverse phase high performance liquid chromatography (RP-HPLC) was used to identify HBD-2. RESULTS:HBD-2 concentrations in gastric juice, but not in plasma, were significantly higher in H pylori-positive than -negative subjects, albeit the post-treatment levels were unchanged. Immunoreactivity for HBD-2 was exclusively identified in H pylori-infected mucosa by RP-HPLC. HBD-2 concentrations in gastric juice correlated with histological degree of neutrophil and mononuclear cell infiltration in the corpus. IL-1beta levels correlated with those of IL-8, but not HBD-2. Plasma and gastric juice HBD-1 concentrations were similar in H pylori-infected and uninfected subjects. CONCLUSION: Our results place the beta-defensins, especially HBD-2, in the front line of innate immune defence. Moreover, HBD-2 may be involved in the pathogenesis of H pylori-associated gastritis, possibly through its function as immune and inflammatory mediator.
Authors: A Wada; K Ogushi; T Kimura; H Hojo; N Mori; S Suzuki; A Kumatori; M Se; Y Nakahara; M Nakamura; J Moss; T Hirayama Journal: Cell Microbiol Date: 2001-02 Impact factor: 3.715
Authors: Y Hamanaka; M Nakashima; A Wada; M Ito; H Kurazono; H Hojo; Y Nakahara; S Kohno; T Hirayama; I Sekine Journal: Gut Date: 2001-10 Impact factor: 23.059
Authors: T Hiratsuka; M Nakazato; Y Date; J Ashitani; T Minematsu; N Chino; S Matsukura Journal: Biochem Biophys Res Commun Date: 1998-08-28 Impact factor: 3.575
Authors: H Isomoto; K Inoue; H Furusu; A Enjoji; C Fujimoto; M Yamakawa; Y Hirakata; K Omagari; Y Mizuta; K Murase; S Shimada; I Murata; S Kohno Journal: Aliment Pharmacol Ther Date: 2003-07-01 Impact factor: 8.171
Authors: David J McGee; Alika E George; Elizabeth A Trainor; Katherine E Horton; Ellen Hildebrandt; Traci L Testerman Journal: Antimicrob Agents Chemother Date: 2011-04-04 Impact factor: 5.191
Authors: Shauna Schroeder; Zachary D Robinson; Joanne C Masterson; Lindsay Hosford; Wendy Moore; Zhaoxing Pan; Rachel Harris; Rhonda F Souza; Stuart Jon Spechler; Sophie A Fillon; Glenn T Furuta Journal: Pediatr Res Date: 2013-02-05 Impact factor: 3.756
Authors: Malte Book; QiXing Chen; Lutz E Lehmann; Sven Klaschik; Stefan Weber; Jens-Christian Schewe; Markus Luepertz; Andreas Hoeft; Frank Stuber Journal: Crit Care Date: 2007 Impact factor: 9.097
Authors: Sabine Nuding; Michael Gersemann; Yoshio Hosaka; Sabrina Konietzny; Christian Schaefer; Julia Beisner; Bjoern O Schroeder; Maureen J Ostaff; Katunori Saigenji; German Ott; Martin Schaller; Eduard F Stange; Jan Wehkamp Journal: PLoS One Date: 2013-09-11 Impact factor: 3.240